At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer.The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on the cancer’s genetic makeup. This new era of precision medicine offers the potential for innovative treatments that are safer and more effective for patients with certain cancers.We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
|Bank Name||Kura Oncology, Inc.|
|Chairman||Dr. Troy Edward Wilson|
|CEO||Dr. Troy Edward Wilson|